---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-128896"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:12:38.623174+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports $159.5M cash as of March 31, 2023; runway into Q4 2024

## Summary
- Cash and marketable securities totaled $159.5M as of March 31, 2023 (preliminary, unaudited).
- Company confirms cash runway extends into at least the fourth quarter of 2024.
- Preliminary estimate subject to change; actual results may differ materially.
- Update provided in connection with virtual investor event on May 1, 2023.

## SEC filing metadata
- accession: 0001193125-23-128896
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/0001193125-23-128896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/d505148d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-128896
- JSON: https://secwatch.observer/filing/0001193125-23-128896.json
- Plain text: https://secwatch.observer/filing/0001193125-23-128896.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported preliminary financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: preliminary results
  source text: Acrivon Therapeutics, Inc. (the “Company”) will be updating its corporate presentation to include disclosure that the Company had $159.5 million of cash and marketable securities as of March 31, 2023 and to confirm its cash runway into at least the fourth quarter of 2024. Because the Company’s financial results for the three months ended March 31, 2023 have not been finalized or audited, the preliminary statement of the Company’s cash and marketable securities as of March 31, 2023 in this Item 2.02 is subject to change
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/0001193125-23-128896-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.